NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
Clinical Trials
44 trialsNCT02682641 2024-02-26
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Unknown
NCT06224309 2024-02-09
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Unknown
NCT02471391 2023-08-21
AIM
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05020392 2023-07-25
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Unknown
NCT05888701 2023-06-05
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.
University of Milano Bicocca
Unknown
NCT02632396 2023-05-09
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission
Emory University
Phase 1/2 Unknown
NCT03891355 2022-09-15
FIL_KLIMT
Fondazione Italiana Linfomi - ETS
Phase 2 Unknown
NCT05504603 2022-08-17
Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05486013 2022-08-03
Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Unknown
NCT05444322 2022-07-11
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT05429918 2022-06-23
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
Peking University Third Hospital
Unknown
NCT05406154 2022-06-06
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
Peking University Third Hospital
Unknown
NCT03629873 2022-01-03
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05076097 2021-11-11
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04736914 2021-08-26
Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT04952974 2021-07-07
MALYZOMA-II
University Hospital, Strasbourg, France
Unknown
NCT04767308 2021-02-23
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Huazhong University of Science and Technology
Phase EARLY_PHASE1 Unknown
NCT04407845 2020-06-09
FABRIC
European Georges Pompidou Hospital
Unknown
NCT04127916 2020-03-18
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
Samsung Medical Center
Unknown
NCT04109872 2020-02-05
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Unknown
NCT03185494 2019-04-17
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02652910 2019-02-27
MeCAR
Xinqiao Hospital of Chongqing
Phase 1/2 Unknown
NCT02991638 2018-04-12
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
The University of Hong Kong
Phase 3 Unknown
NCT02354313 2018-02-09
MCL0208
Fondazione Italiana Linfomi - ETS
Phase 3 Unknown
NCT03265158 2017-08-29
BMPB
Royal Marsden NHS Foundation Trust
Unknown
NCT01439750 2017-08-07
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Milton S. Hershey Medical Center
Phase 1 Unknown
NCT02685670 2017-03-16
MatchCART
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Phase 1/2 Unknown
NCT02721407 2017-03-10
MendCART
Xinqiao Hospital of Chongqing
Phase 1 Unknown
NCT00209209 2017-03-07
MCLelderly
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT03016988 2017-01-11
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Phase 2 Unknown
NCT01933711 2016-05-13
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
University Hospital Heidelberg
Phase 3 Unknown
NCT01864889 2016-01-28
CART19
Chinese PLA General Hospital
Phase NA Unknown
NCT01735604 2015-09-29
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02134262 2014-11-06
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Phase 1/2 Unknown
NCT02267590 2014-10-17
CLARITY
Royal Marsden NHS Foundation Trust
Unknown
NCT02081937 2014-03-11
CART-19 Immunotherapy in Mantle Cell Lymphoma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01678417 2012-09-05
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Korea Cancer Center Hospital
Phase 2 Unknown
NCT00397800 2012-08-28
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich
Phase 1/2 Unknown
NCT01221103 2011-09-13
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Southern Europe New Drug Organization
Phase 1/2 Unknown
NCT01322776 2011-03-25
Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown
NCT00946374 2009-07-27
HD-MCL2003
Heidelberg University
Phase 2 Unknown
NCT00261612 2006-10-18
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
Medical University of Vienna
Phase 2 Unknown